Comment from Breakthrough T1D

Summary: Breakthrough T1D, a type 1 diabetes research and advocacy organization, supports the FDA's Expedited Investigational New Drug Pilot Program. They advocate for specific modifications, including establishing a cell and gene therapy (CGT) specialization track, prioritizing products with high unmet medical needs, and ensuring equitable access for smaller innovators.